We report the beneficial effects of calcium infusions in a child with hereditary resistance to 1,25(OH)2D and alopecia. This patient after transient responsiveness to vitamin D derivatives became unresponsive to all therapy despite serum 1,25(OH)2D concentrations maintained at levels -100-fold normal. A 7-mo trial with calcium infusions led to correction of biochemical abnormalities and healing of rickets. Bone biopsies (n = 3) showed a normal mineralization and the disappearance of the osteomalacia. Cultures of bone-derived cells demonstrated a lack of activation of 25-hydroxyvitamin D 24-hydroxylase and osteocalcin synthesis by 1,25(0H)2D3 (10-' and 10' M). These results demonstrate that (a) even in the absence of a normal 1,25(OH)2D3 receptor-effector system in bone cells, normal mineralization can be achieved in humans if adequate serum calcium and phosphorus concentrations are maintained; and (b) calcium infusions may be an efficient alternative for the management of patients with this condition who are unresponsive to large doses of vitamin D derivatives.
Introduction
Hereditary resistance to 1,25- (1) . The underlying defects leading to the resistance of target tissues to 1,25(OH) 2D have not yet been identified. Results of a recent study, in which skin fibroblast extracts from eight such patients were evaluated for the detection and quantitation of 1,25 (OH)2D3 receptors using a monoclonal antibody to the chick receptor molecule, suggest that resistance to the hormonal form of the vitamin is the consequence of structural variations in the receptor molecule and is not due to defective receptor synthesis (2) . Whatever the basic molecular defect(s), the accumulating data clearly show a great heterogeneity in the clinical features ofpatients with hereditary resistance to 1,25(OH)2D and in their response to therapy with vitamin D derivatives (1) . Favorable clinical responses to the administration ofpharmacological doses of native vitamin D, 25(OH)D3, la(OH)D3, 1,25(OH)2D3 (3) (4) (5) (6) (7) (8) (9) (10) , or 24,25(OH)2D3 (11) have been reported in some patients. However , it has been shown that other patients with resistance to 1,25(0H)2D3 may remain unresponsive to similar therapeutic trials (10, 12, 13) or, after prolonged remission oftheir symptoms, become completely refractory to treatment with vitamin D derivatives (10) . The absence of effective therapy may have severe consequences, especially in children. Death during the first three years of life, mainly due to pulmonary complications or hypocalcemic convulsions, has been reported in six children belonging to three affected kindreds (10, 1 1). Dwarfism, skeletal deformities, myopathy, and bone pain may seriously handicap such patients (10, 14) .
A new model for the management of patient with hereditary resistance to 1,25(OH)2D3 unresponsive to large doses of vitamin D derivatives is described in the present report. The evaluation of 1,25(OH)2D3 action in cultured bone-derived cells obtained from our patient at the time this treatment was initiated and 3 mo after cessation of this therapy has provided the first demonstration that, in humans, normal mineralization can be achieved even in the absence of a normal 1,25(OH)2D receptoreffector system in bone cells.
Methods
Patient and treatment regimens. The detailed case history of patient A up to the age of 8 yr, from November 1974 to May 1983 , has been previously reported (10) . This child, born in 1974 to consanguinous parents, had congenital alopecia, and indications of rickets were first seen on radiographs when she was aged 7 mo. Three ofher seven siblings had previously died at '-3 The calcium solution, i.e., 500-1,000 mg ofelemental calcium as calcium glucono-galactogluconate (calcium-Sandoz ampoules, Sandoz Laboratories, Rueil Malmaison, France) in 500 ml of 5% dextrose, was perfused from 0800 p.m. to 0800 a.m., using a peristaltic pump. The amount of elemental calcium infused was progressively increased from 500 mg to 1,000 mg over the first 10 d of nocturnal calcium infusions; this dosage was maintained for 1 mo. The patient subsequently received 750 mg elemental calcium per 12 h daily for the next 4 mo. Thereafter, the treatment was continued on a thrice-weekly infusion program providing 750 mg of elemental calcium per infusion. At the end of -6 mo of intracaval infusions the catheter was withdrawn and the thrice-weekly nocturnal infusion therapy was continued using an arteriovenous fistula that had been created in her left forearm under general anesthesia. The calcium infusions were stopped after a total period of 7 (18) . The concentration determined by these techniques corresponds to the sum of the vitamin D2 and D3 forms of each metabolite. The normal ranges for children in northern France are: 6-30 ng/ ml for 25(OH)D; 1-3 ng/ml for 24,25(OH)2D; and 20-80 pg/ml in children between 2 and 10 yr of age for 1,25(OH)2D (n = 26).
Bone studies. Bone specimens were obtained from anterior iliac crests with the trepine of Bordier. Three biopsies were performed while the child was under general anesthesia for required surgical procedures, i.e., insertion of intracaval catheter, creation of an arteriovenous fistula, surgical repair of this fistula. Each bone specimen was cut longitudinally in halfusing a sharp lancet; one halfwas processed for quantitative histology, and the other used for bone-derived cell cultures.
(a) Histomorphometry. The samples were fixed in a cacodylate-buffered solution ofglutaraldehyde (2.5%) and formaldehyde and embedded in methylmetacrylate without prior decalcification. 5-and 10-pm thick sections were cut with a microtome (A. 0. Spencer, Buffalo, NY) equipped with a tungsten-carbide cutting edge and stained with toluidine blue (pH 6.4) or examined, unstained, by fluorescent microscopy under a Zeiss Universal microscope. Morphometric data were obtained with a Zeiss Morphomat 10 at X 200 magnification for volume data, and at X 500 magnification for all other parameters studied. The following measurements were made. Bone volume, expressed as the percent of spongiosa volume composed of mineralized and nonmineralized bone matrix; os- (b) Bone-derived cell cultures. Trabecular bone specimens obtained from patient A and from four age-matched controls, i.e., orthopedic patients free from disturbances of calcium and/or phosphorus metabolism, were cut into fragments (-0.5 cm in diameter) and plated out into 10-cm tissue culture dishes containing modified BGJ medium (Bio-Merieux, Lyon, France) supplemented with 30% fetal calfserum (Flow Laboratories, Puteaux, France), 100 U/ml penicillin, 50 pg/ml streptomycin, and 2.5 pg/ml fungizone (Boehringer Mannheim Biochemicals, Strasbourg, France). After 48 h incubation at 370C in a humidified atmosphere of95% air/5% CC2, the medium containing explants and migrating cells was filtered through sterile bolting cloth (35-pm mesh). The cell suspension thus obtained was sedimented at 400 g for 10 min in a desktop centrifuge (Hettich EBA, Ceralabo, Aubervilliers, France) and the cells resuspended in BGJ medium containing 10% fetal calfserum. They were then plated out in 3.5-cm diameter culture dishes (n = 12-20 dishes, 106 cells/dish) in 2 ml modified BGJ medium supplemented with antibiotics and 10% fetal calf serum. Medium was renewed every 48 h. The cells reached confluency after 3 to 5 wk in culture. Confluent cells were washed once with serum-free BGJ medium and incubated in 2 ml serumfree BGJ for an additional 6 h before being used for 25-hydroxyvitamin D3-24-hydroxylase (24-hydroxylase) stimulation and osteocalcin (BGP) production tests.
24-Hydroxylase assay. The incubation medium was removed and replaced by 2 ml fresh serum-free medium supplemented with synthetic 1,25(OH)2D3 (final concentration 10-' M) or its ethanol solvent (not exceeding 0.2%). After a further incubation period of 18 h at 37°C, cells were incubated for 90 min in 5% C02/95% air with 0.1 ,uCi [3H-26,27]25(OH)D3 (Radiochemical Center, Amersham, United Kingdom; sp act 18.5 Ci/mmol) in 0.02 ml ethanol. At the end of the incubation, cells and their incubation medium were transferred to centrifuge tubes and extracted with methanol-chloroform (2:2, vol/vol). The methanolaqueous phase was centrifuged for 10 min at 600 g, and the pellet was frozen and stored for determination ofDNA content (23) . The chloroform phases were dried under a stream of nitrogen, dissolved in n-hexaneisopropanol (92:8, vol/vol), and injected into a high pressure liquid chromatograph (Waters Associates, Milford, MA) equipped with a sample injector (model U6K) and a radial compression module RCH 100. The column, a Radial-Pak B (8 mm X 10 cm) cartridge, was eluted with nhexane-isopropanol at a flow rate of 3 ml/min. Fractions ofthe effluent were collected every 30 s for 15 min. An aliquot ofeach collected fraction was evaporated and dissolved in 5 ml counting solution. Radioactivity in the fractions was measured using a liquid scintillation spectrometer model SL30 (Intertechnique, Plaisir, France). The putative 24,25(OH)2D3 metabolite, when detected, was further characterized by co-chromatography with synthetic 24,25(OH)2D3 on high performance liquid chromatography (HPLC) using the above system and a straight-phase system in which samples were eluted with dichloromethane-isopropanol (95:5, vol/vol), and by a periodate cleavage procedure (24) BGPproduction. Cells were incubated for 18 h in serum-free medium supplemented either with 1,25(OH)2D3 (10-9 M) or its ethanol solvent. The medium was removed and kept frozen before subsequent BGP determination. BGP was measured (Dr. P. Delmas, Hopital Alexis Carel, Lyon, France) using a previously described modification (25) of the radioimmunoassay described by Price and Nishimoto (26) .
Informed consent was obtained from the patient's parents for all the studies and treatment described in accordance with institutional and governmental guidelines.
Results
In this patient, who had remained unresponsive to large doses of vitamin D derivatives for 3 yr, two different treatment regimens, i.e., high-calcium high-lactose diet and calcium infusions, were assessed.
Effect ofa high-cakium-high-lactose diet. The patient was 9-yr-old, weighed 23.2 kg, and measured 113 cm (-3.4 SD) in height when the high-calcium, i.e., 2,250 mg/d, high-lactose, i.e., 62 g/d, diet was initiated. Her skeletal radiograms showed ricketic alterations, coxa vara, and genu valgum. Previous highdosage 25(OH)D3 (5 mg/d) therapy had been stopped for 3 mo. The termination of high-dosage 25(OH)D3 therapy induced no significant changes in the biochemical parameters (Table I) , although circulating concentrations of25(OH)D and 1,25(OH)2D decreased from very high levels to 16 ng/ml and 89 pg/ml, respectively. These observations further support the assumption that high-dosage 25(OH)D3 therapy had been totally ineffective from the age of 6 yr. The decrease in serum 25(OH)D concentration observed after termination of high-dosage 25(OH)D3 treatment ( Fig. 1) Biochemical parameters (Fig. 2) . Repeated monitoring of her serum calcium and phosphorus concentrations, i.e., every 4 h during the infusion, then at the beginning and end of each infusion, and eventually once or twice weekly, showed that serum calcium remained in the normal range except for two transient episodes when it reached 2.65-2.70 mmol/liter. Serum phosphorus concentrations progressively increased and remained in the normal range after 2 mo oftreatment. Serum alkaline phosphatase decreased. Normalization ofthis parameter was obtained in the fourth month of therapy. The generalized hyperaminoaciduria with normal serum amino acid concentration observed before treatment was no longer present in the third month of treatment (not shown). Serum iPTH concentration (Fig. 2 ) was found to be normal after 6 mo of therapy but increased again to 76 pg/ml when the infusion regimen was stopped. Measurements of circulating vitamin D metabolites concentrations during the whole period of nocturnal infusions showed that 25(OH)D levels remained in the normal range, i.e., 9.3+2.2 ng/ ml (n = 7). Serum 1,25(OH)2D concentrations were usually high, ranging from 33 to 163 pg/ml (112±46 pg/ml, mean±1 SD, n = 6), and serum 24,25(OH)2D concentrations were variable: low or normal during the first month of calcium infusion, increasing to 4.5 and 7.5 ng/ml in the second and fourth month of therapy, and returning to normal, i.e., 1.4 The skeletal radiograms showed severe metaphyseal abnormalities characteristic of overt rickets and a demineralized bone with coarse trabeculations at the time the calcium infusion was initiated (Fig. 3 A) . 3 wk later, the process of healing of these lesions was clearly visible (not shown). Further improvement was observed after 3 mo of nocturnal calcium infusions (not shown), leading to healing of metaphyseal lesions and restoration of a normal trabecular appearance at the end of4 mo oftherapy (Fig. 3 B) . Thereafter, repeated radiological examination showed no symptoms of rickets either when the child was changed to a thrice-weekly calcium infusion program or during the 3 mo after termination of this treatment (not shown).
The morphometric data of the three bone biopsies (Table  II) confirmed the dramatic changes observed in the skeletal radiograms. The initial biopsy revealed typical histological signs of severe osteomalacia, with excess osteoid volume, increased osteoid surface, and wide osteoid seams associated with a very low percentage ofosteoid surface showing a mineralization front. The interface between osteoid and mineralized matrix was sharp in most trabeculae, bearing a few large calcified clusters. Occasionally, the interface was blurred and composed of large zones of fine granules and some osteoid could be observed deep within the calcified matrix. Marrow fibrosis was absent and the percent of trabecular surface covered by osteoclasts was in the normal range. Although the number of osteoclasts was increased, these were inactive in contact with the osteoid tissue. The number of osteoblasts was slightly increased. The second biopsy, obtained after 4 mo of calcium infusion therapy, showed normalization of the osteoid volume and osteoid seam thickness. Osteoid surface had decreased and the extent of the mineralization front was greatly increased as compared with the values obtained in the first biopsy. Moreover, the pattern of mineralization had become normal. The mineralization front appeared as a thin line of fine granules on toluidine-blue-stained sections, and as a clearly defined fluorescent line on unstained sections examined under ultraviolet light. The osteoclast number was found to be in the normal range. On the third biopsy, obtained after cessation ofthe calcium infusion program, osteomalacia had disappeared. All parameters that reflect matrix formation and mineralization, i.e., osteoid volume, osteoid surface, mineralization front, osteoid width, and mineralization rate, were not different from controls (Table II) . A few trabeculae still contained small osteoid fragments, remnants of the earlier osteomalacic lesions. Bone-derived cell cultures were obtained from two of the patient's iliac crest biopsies performed 24 h before and 3 mo after the end ofthe nocturnal calcium infusion program. Growth and morphology ofthese cultures were similar to that ofcontrol cultures (n = 4). In addition, the patient's cells were sensitive to PTH, as shown by increased cAMP production after incubation with bPTH-( 1-34) (Silve, A., B. Groose, C. Tau, H. Garabedian, J. Fritsch, P. D. Delmas, G. Cournot-Witmer, and S. Balsan, manuscript in preparation). However, no 24-hydroxylase activity could be detected in the patient's bone-derived cell cultures (vs. 
Discussion
The major physiological role of 1 ,25(OH)2D is to act as a calciumregulating hormone by promoting intestinal absorption of calcium and mobilization of calcium from bone (27, 28) . This metabolite also enhances intestinal absorption of phosphorus, independent ofits action on the intestinal translocation ofcalcium. phosphorus has been documented in all the patients having hereditary resistance to 1,25(OH)2D, in whose intestinal absorption of calcium and phosphorus was investigated using external balance studies and/or fractional 47Ca absorption tests (7, 8, 14) . and total freedom of movement, even during sleep. However, such a route can only be used transiently and usually for no longer than 6-9 mo. It also requires adherence to strict rules of asepsis. Consequently, parenteral calcium infusions via an intracaval catheter should never be used in departments that do not possess a highly specialized unit with a medical and nursing staff trained for such treatment. To date, hemodialysis centers are much more numerous and widespread than parenteral nutrition units. Hence, it can be assumed that, for most patients, the route of administration selected will be an arteriovenous fistula. The one inconvenience of this route is that a delay of 2-4 wk is usually necessary before the fistula can be used.
The present data also have theoretical implications. Bone is one of the major target tissues of 1,25(OH)2D3 (27, 28) , and specific binding ofthis metabolite to bone cells has been recently documented (36) . It is also well established that 1,25(OH)2D3 stimulates osteocalcin synthesis (37), and 25(OH)D3-24 hydroxylase (38) . Previou's studies on cultured fibroblasts from our patient showed abnormalities in cytosol binding and nuclear uptake of [3H]1,25(OH)2D3 (10 it must be via a mechanism that does not involve the hormone receptor-effector system. In effect, our data provide convincing evidence that, in humans, normal mineralization can be achieved even in the absence of a normal 1,25(0H)2D3 receptor-effector system, provided that normal circulating calcium and phosphorus concentrations are maintained.
